Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC

NCT00709761 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Breast

Interventions

DRUG: Lapatinib/nab-Paclitaxel

Sponsor

Novartis Pharmaceuticals